HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
Harrow Q1 Earnings Call Highlights
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
Harrow Announces First Quarter 2026 Financial Results
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
State of Alaska Department of Revenue Acquires 14,065 Shares of Harrow, Inc. $HROW
Harrow: Now Is The Buy Time
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
LogiCare3PL Selected as Distribution Partner by Harrow
Harrow: Probably A Short-Term Market Overreaction
Harrow Inc (HROW) Stock Up 3.3% and Still Undervalued -- GF Score: 86/100
JPMorgan Chase & Co. Sells 42,246 Shares of Harrow, Inc. $HROW
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market
What Moved Markets This Week
These Analysts Revise Their Forecasts On Harrow Following Q4 Results
Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade)
Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript
Harrow Shares Collapse, Another Opportunity?
Why Is Eye-Disease-Focused Harrow Stock Falling Today?
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
Harrow (HROW) Misses Q4 Earnings Estimates
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth
Brokerages Set Harrow, Inc. (NASDAQ:HROW) Price Target at $71.43
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength?
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update
Harrow: Flirting With Missing 2025 Revised Guidance
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of “Moderate Buy” from Analysts
Squarepoint Ops LLC Has $640,000 Stock Holdings in Harrow, Inc. $HROW
Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS
Harrow, Inc. $HROW Shares Purchased by Geode Capital Management LLC
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45%
Harrow to Present at Two Investor Conferences in December
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Private Capital's Strategic Moves: Spotlight on Matthews International Corp
Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript
Harrow Announces Third Quarter 2025 Financial Results
Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025